View:
United States securities and exchange commission logo
May 13, 2024
Troy Ignelzi
Chief Financial Officer
Rapport Therapeutics, Inc.
1325 Boylston Street, Suite 401
Boston, MA 02215
Re: Rapport
Therapeutics, Inc.
Amendment No. 1 to
Draft Registration Statement on Form S-1
Submitted April 29,
2024
CIK No. 0002012593
Dear Troy Ignelzi:
We have reviewed your amended draft registration statement and have
the following
comments.
Please respond to this letter by providing the requested
information and either submitting
an amended draft registration statement or publicly filing your
registration statement on
EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your
response.
After reviewing the information you provide in response to this
letter and your amended
draft registration statement or filed registration statement, we may
have additional
comments. Unless we note otherwise, any references to prior comments are
to comments in our
April 24, 2024 letter.
Amendment No. 1 to Draft Registration Statement submitted April 29, 2024
Introduction to RAP-219, page 4
1. We note your revised
disclosure on page 5 and elsewhere in response to prior comment
1. With reference to
the second full sentence on page 5, and with a view to clarified
disclosure, please tell
us whether there is preclinical data demonstrating that RAP-219 has
minimal or no
expression in the cerebellum, brainstem and other brain areas that are
critical for normal
brain functions. In this regard, we note that the preclinical study
presented on page 121
appears to have been conducted using a molecule that is not RAP-
219.
Troy Ignelzi
FirstName LastNameTroy
Rapport Therapeutics, Inc. Ignelzi
Comapany
May NameRapport Therapeutics, Inc.
13, 2024
May 13,
Page 2 2024 Page 2
FirstName LastName
RAP-219 Preclinical Studies, page 121
2. We note your revised disclosure in response to prior comment 7. Please
revise to explain
whether these other TARPy8 NAMS are third-party molecules or
proprietary ones and
why preclinical testing was conducted on these molecules and not on
RAP-219. To the
extent that any of the preclinical data presented relates to RAP-482,
please identify the
preclinical study and revise the disclosure on page 19 to discuss the
reason(s) why RAP-
482 received a full clinical hold from the FDA.
Please contact Jenn Do at 202-551-3743 or Daniel Gordon at 202-551-3486
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Tamika Sheppard at 202-551-8346 or Joe McCann at 202-551-6262 with any other
questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Justin Platt